Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour efficacy and tolerability of preservative-free tafluprost + timolol fixed combination after switch from BAK-preserved latanoprost in glaucoma or ocular hypertension
2019-003426-24Phase 4Completed
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost + timolol and latanoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Fondazione G.B. Bietti-IRCCS. Primary endpoint: Mean 24-hour absolute intraocular pressure reduction. Started Jul 2020; status: completed.
02
Drugs
tafluprost + timolollatanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2019-003426-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003426-24.